Cambrex is a pharmaceutical company based in the United States that specializes in the development and manufacturing of active pharmaceutical ingredients (APIs) and finished dosage forms (FDFs) for the global pharmaceutical industry. Founded in 1981, Cambrex initially focused on providing purified enzymes to customers in the pharmaceutical and biotech industries. Over the years, the company expanded its offerings to include custom synthesis, process development, analytical services, and formulation development.

Today, Cambrex is recognized as a leading global provider of small molecule APIs and FDFs for both branded and generic drugs. Cambrex is headquartered in East Rutherford, New Jersey. The company's headquarters houses its executive management, business development, finance, and other administrative functions.

The company operates globally with manufacturing facilities in North America, Europe, and Asia. Its notable subsidiaries include Cambrex Profarmaco Milan S. p.

A. Cambrex also has joint ventures in China and India, further expanding its global presence. In terms of market position, Cambrex is considered a significant player in the pharmaceutical services industry.

It has established strong relationships with major pharmaceutical companies and has a reputation for delivering high-quality products and services. The company's global sales have consistently grown over the years, demonstrating its ability to stay competitive in the market. Cambrex has experienced several noteworthy events and achievements throughout its history.

In 2007, the company acquired the global drug development and manufacturing business of Avecia Pharmaceuticals, expanding its service offerings and customer base. In 2016, Cambrex completed the acquisition of Halo Pharma, enhancing its capabilities in formulation development and finished dosage manufacturing. As of the latest available information, Cambrex was acquired by the private equity firm Permira Funds in August 2019, becoming a privately held company.

This acquisition reflects Cambrex's commitment to strategic growth and further development in the pharmaceutical industry. In conclusion, Cambrex is a leading pharmaceutical company based in the United States, specializing in the development and manufacturing of APIs and FDFs. With its global operations, strong market position, and notable achievements, Cambrex continues to play a significant role in the pharmaceutical services industry